Efficacy of a nanocochleate-encapsulated 3,5-diaryl-s-triazole derivative in a murine model of graft-versus-host disease

Transplantation

Volumn 86, Issue 1, 2008, Pages 171-175

  Campo, Silvia ^a   Arseni, Brunilde ^a   Rossi, Stefania ^a   D'Alessio, Valeria ^a   Lu, Ruying ^b   Ngoje, Joel ^b   Ahl, Patrick L ^b   Bonitz, Susan ^b   Mannino, Raphael ^b   Di Mitri, Diletta ^c   Battistini, Luca ^c   Carminati, Paolo ^a   De Santis, Rita ^a   Ruggiero, Vito ^a  

^a Sigma Tau SpA   (Italy)

^b BioDelivery Syst Intl Inc   (United States)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

CD62L; Chemokines; Graft versus host disease; ST1959 3 5 Diaryl s triazole

Indexed keywords

CHEMOKINE; DRUG CARRIER; HEMOGLOBIN; NANOCOCHLEATE; ST 1959; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; 3 (2 ETHYLPHENYL) 5 (3 METHOXYPHENYL) 1H 1,2,4 TRIAZOLE; 3-(2-ETHYLPHENYL)-5-(3-METHOXYPHENYL)-1H-1,2,4-TRIAZOLE; IMMUNOSUPPRESSIVE AGENT; NANOCAPSULE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DONOR; DRUG EFFICACY; ERYTHROCYTE COUNT; EXPERIMENTAL MODEL; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; LETHALITY; LEUKOCYTE COUNT; MOUSE; NANOENCAPSULATION; NONHUMAN; NORMOCHROMIC NORMOCYTIC ANEMIA; PRIORITY JOURNAL; SPLEEN; SURVIVAL RATE; THROMBOCYTE; ANEMIA; ANIMAL; BLOOD; BLOOD EXAMINATION; C57BL MOUSE; CD4+ T LYMPHOCYTE; DISEASE MODEL; DRUG EFFECT; DRUG FORMULATION; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; TIME;

ADMINISTRATION, ORAL; ANEMIA; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES; DISEASE MODELS, ANIMAL; DRUG COMPOUNDING; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC TESTS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED C57BL; NANOCAPSULES; TIME FACTORS; TRIAZOLES;

EID: 49849104757     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31817ba761     Document Type: Article

References (21)

1. Galliani G, Assandri A, Gallico L, et al. A new non-hormonal pregnancy - Terminating agent. Contraception 1981; 23: 163.
2. Mistrello G, Galliani G, Assandri A, et al. Immunological profile of DL111-IT, a new immunosuppressant agent. Immunopharmacology 1985; 10: 163.
3. Ruggiero V, Albertoni C, Rosi A, et al. Efficacy of ST1959 in murine models of autoimmunity and insights into its peculiar immunomodu-latory profile. Int J Immunother 2003; 19: 1.
4. Stasi MA, Ruggiero V, Ursillo A, et al. Ameliorating effects of the immunomodulator 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole in an experimental model of colitis in the rat. Eur J Pharmacol 2004; 494: 263.
5. Campo S, Albertoni C, D'Alessio V, et al. ST1959 protects from mortality inamurine modelof acute graft-versus-host disease. Presented at the Sixteenth European Congress of Immunology, Paris, 2006; p. 406 Abstract Book.
6. Zarif L. Elongated supramolecular assemblies in drug delivery. J Control Release 2002; 81: 7.
7. Zarif L. Drug delivery by lipid cochleates. Methods Enzymol 2005; 391: 314.
8. DelmasG,ParkS,Chen ZW,etal. Efficacyoforally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimi-crob Agents Chemother 2002; 46: 2704.
9. Santangelo R, Paderu P, Delmas G, et al. Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. Antimicrob Agents Chemother 2000; 44: 2356.
10. Zarif L, Graybill JR, Perlin D, et al. Antifungal activity of amphoter-icin B cochleates against Candida albicans infection in a mouse model. Antimicrob Agents Chemother 2000; 44: 1463.
11. Segarra I, Movshin DA, Zarif L. Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system. J Pharm Sci 2002; 91: 1827.
12. Hakim FT, Sharrow SO, Payne S, et al. Repopulation of host lympho-hematopoietic systemsby donor cells during graft-versus-host reaction in unirradiated adultF1mice injected with parental lymphocytes. J Immunol 1991; 146: 2108.
13. De Santis R, Angelini DF, Cencioni MT, et al. ST1959 is an effective suppressor of antigen specific gamma delta T cell responses in healthy and multiple sclerosis individuals. J Neuroimmunol 2004; 154: 209.
14. Lindstedt R, Petronzelli F, Manganello S, et al. Inhibitory effects of ST1959 on the binding of NFAT2 to its target sequence in Jurkat cells and human PBMC. Minerva Biotecnologica 2004; 16: 15.
15. Bevilacqua MP, Nelson RM. Selectins. J Clin Invest 1993; 91: 379.
16. Li B, New JY, Yap EH, et al. Blocking L-selectin and alpha4-integrin changes donor cell homing pattern and ameliorates murine acute graft versus host disease. Eur J Immunol 2001; 31: 617.
17. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, et al. Leukocyte migration and graft-versus-host disease. Blood 2005; 105: 4191.
18. Terwey TH, Kim TD, Kochman AA, et al. CCR2 is required for CD8-induced graft-versus-host disease. Blood 2005; 106: 3322.
19. Wysocki CA, Burkett SB, Panoskaltsis-Mortari A, et al. Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning. J Immunol 2004; 173: 845.
20. Murai M, Yoneyama H, Ezaki T, et al. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol 2003; 4: 154.
21. Pezzotta A, Mister M, Cravedi P, et al. Effect of a novel immunosup-pressant, ST1959, on the immune system and renal allograft survival in rats. Transplantation 2005; 80: 231.